Product Image

Contributor Information

  • Name Taija Makinen
  • Institute Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details

  • Tool name: Prox1CreERT2 Mouse
  • Tool type: Experimental models
  • Tool sub-type: Mouse
  • Model: Conditional KO
  • Conditional: Yes
  • Conditional description: Cre-ER transgenic
  • Genetic background and cross history: A cDNA encoding tamoxifen inducible Cre recombinase (CreERT2) followed by SV40 polyadenylation signal was introduced into the start codon of Prox1 in BAC clone RP23-190F21 using homologous recombination in bacteria. The construct was validated by PCR and Southern blot analyses, and used for pronuclear injection into fertilised mouse oocytes. Two founder lines were generated and tested by timed matings with Cre reporter strains, followed by 4-OHT administration, for specificity and efficiency of Cre-mediated recombination. One of the founder lines that gave efficient recombination in all Prox1-expressing tissues was kept for further studies.
  • Zygosity: Heterozygous
  • Description: Allows specific and temporally controlled cre-loxP recombination (gene inactivation/activation) in Prox1-expressing tissues, including lymphatic endothelia. Efficient recombination is observed during all developmental stages (embryonic, postnatal) and in adults. Currently no other models are available that allow such efficient and specific targetting of lymphatic vasculature. Transgenic mouse expressing tamoxifen-inducible creERT2 under the control of Prox1 gene promoter
  • Research area: Tissue-specific biology; Cell signaling and signal transduction; Genetics; Neurobiology
  • Production details: A cDNA encoding tamoxifen inducible Cre recombinase (CreERT2) followed by SV40 polyadenylation signal was introduced into the start codon of Prox1 in BAC clone RP23-190F21 using homologous recombination in bacteria. The construct was validated by PCR and Southern blot analyses, and used for pronuclear injection into fertilised mouse oocytes. Two founder lines were generated and tested by timed matings with Cre reporter strains, followed by 4-OHT administration, for specificity and efficiency of Cre-mediated recombination. One of the founder lines that gave efficient recombination in all Prox1-expressing tissues was kept for further studies.

  • For Research Use Only

Target Details

  • Target: Prox1

Application Details

Handling

  • Shipping conditions: Embryo/Spermatoza- Dry Ice

Documentation

References

  •   Bianchi et al. 2015. PLoS One. 10(4):e0122976. PMID: 25849579.
  •   Martinez-Corral et al. 2015. Circ Res. 116(10):1649-54. PMID: 25737499.
  •   Rouhani et al. 2015. Nat Commun. 6:6771. PMID: 25857745.
  •   Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.
  •   A transgenic Prox1-Cre-tdTomato reporter mouse for lymphatic vessel research.
  •   Nonvenous origin of dermal lymphatic vasculature.
  •   Park et al. 2014. J Clin Invest. 124(9):3960-74. PMID: 25061877.
  •   Aspelund et al. 2014. J Clin Invest. 124(9):3975-86. PMID: 25061878.
  •   The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel.
  •   Lymphatic regulator PROX1 determines Schlemm's canal integrity and identity.
  •   Tatin et al. 2013. Dev Cell. 26(1):31-44. PMID: 23792146.
  •   Planar cell polarity protein Celsr1 regulates endothelial adherens junctions and directed cell rearrangements during valve morphogenesis.
  •   Chen et al. 2012. J Clin Invest. 122(6):2006-17. PMID: 22622036.
  •   Blood flow reprograms lymphatic vessels to blood vessels.
  •   Sabine et al. 2012. Dev Cell. 22(2):430-45. PMID: 22306086.
  •   Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation.
  •   Bazigou et al. 2011. J Clin Invest. 121(8):2984-92. PMID: 21765212.
  •   Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice.